^
    over2years
    Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy (clinicaltrials.gov)
    P1, N=7, Suspended, BioNTech Research & Development, Inc. | Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Sep 2022 --> Feb 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    BNT321 • MVT-1075
    almost3years
    Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy (clinicaltrials.gov)
    P1, N=7, Suspended, BioNTech Research & Development, Inc. | Trial completion date: Dec 2021 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Sep 2022
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    BNT321 • MVT-1075
    almost4years
    Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy (clinicaltrials.gov)
    P1, N=7, Suspended, BioNTech Research & Development, Inc. | Trial completion date: Dec 2020 --> Dec 2021 | Active, not recruiting --> Suspended | Trial primary completion date: Dec 2020 --> Dec 2021
    Clinical • Trial completion date • Trial suspension • Trial primary completion date • Combination therapy
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    BNT321 • MVT-1075